REGN1908-1909

Evidence outlook · lead readout

NCT03838731 · Cat Allergy, Mild Asthma

The completed lead evidence has the design features that historically survive confirmatory trials — randomized, controlled, and adequately powered against a prespecified clinically accepted endpoint.

NCT03838731: This was a randomized, placebo-controlled trial in which neither participants, care providers, investigators, nor outcome assessors knew who received the active drug, and the primary lung-function-based endpoint (time to a drop in breathing capacity after allergen exposure) was met with a statistically significant result favoring treatment.